

Title (en)

COMPOSITIONS FOR TREATING PATHOLOGIES THAT NECESSITATE SUPPRESSION OF GASTRIC ACID SECRETION

Title (de)

ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON PATHOLOGISCHEN ZUSTÄNDEN, DIE DIE SUPPRESSION DER MAGENSÄURESEKRETION ERFORDERN

Title (fr)

COMPOSITIONS POUR LE TRAITEMENT DE PATHOLOGIES QUI NECESSITENT LA SUPPRESSION DES SECRECTIONS D'ACIDE GASTRIQUE

Publication

EP 1658089 A4 20070314 (EN)

Application

EP 04769171 A 20040825

Priority

- IB 2004002745 W 20040825
- US 49793003 P 20030827
- US 54431804 P 20040217

Abstract (en)

[origin: WO2005020879A2] The present invention is related to novel oral compositions comprising an irreversible gastric H<+>/K<+>-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor, pentagastrin (PG) or a PG analogue as an activator of parietal cells in the gastric lumen. In a preferred embodiment, the composition further comprises at least one agent that preserves the availability of PG in the gastric fluids, thus enabling PG to act locally in the stomach. Unexpectedly, the compositions of the present invention exhibit anti-acid activity locally in the stomach that is meal-independent, exhibit fast onset and prolonged inhibition of acid secretion.

IPC 8 full level

A61K 45/06 (2006.01); **A61K 9/00** (2006.01); **A61K 9/20** (2006.01); **A61K 9/46** (2006.01); **A61K 9/50** (2006.01); **A61K 31/4439** (2006.01); **A61K 33/00** (2006.01); **A61K 33/10** (2006.01); **A61K 38/00** (2006.01); **A61K 38/02** (2006.01); **A61K 38/08** (2019.01); **A61K 38/16** (2006.01); **A61K 38/22** (2006.01); **A61K 47/00** (2006.01); **A61P 1/04** (2006.01)

IPC 8 main group level

A61K (2006.01)

CPC (source: EP KR US)

A61K 9/0007 (2013.01 - EP); **A61K 9/2009** (2013.01 - EP); **A61K 9/2081** (2013.01 - EP); **A61K 9/2086** (2013.01 - EP); **A61K 9/5078** (2013.01 - EP); **A61K 9/5084** (2013.01 - EP); **A61K 31/4439** (2013.01 - EP); **A61K 33/00** (2013.01 - EP); **A61K 33/10** (2013.01 - EP); **A61K 38/02** (2013.01 - KR); **A61K 38/08** (2013.01 - EP US); **A61K 38/16** (2013.01 - KR); **A61K 38/2207** (2013.01 - EP); **A61K 45/06** (2013.01 - EP); **A61P 1/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)

- [PX] WO 2004034957 A2 20040429 - VECTA LTD [IL], et al
- [Y] WO 0110405 A1 20010215 - RANBAXY LAB LTD [IN], et al
- [Y] US 4910021 A 19900320 - DAVIS JOHN D [US], et al
- [Y] KATHLEEN PARFITT (ED): "Martindale The Complete Drug Reference", 1999, PHARMACEUTICAL PRESS, LONDON, GB, ISBN: 0 85369 429 X, ISSN: 0263-5364, XP002409837
- [Y] DATABASE WPI Week 199242, Derwent World Patents Index; AN 1992-343803, XP002414819
- See references of WO 2005020879A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2005020879 A2 20050310; **WO 2005020879 A3 20050519**; AU 2004268446 A1 20050310; CA 2536906 A1 20050310; EP 1658089 A2 20060524; EP 1658089 A4 20070314; IL 173944 A0 20060705; JP 2007503427 A 20070222; KR 20060083198 A 20060720; RU 2006109357 A 20071010

DOCDB simple family (application)

IB 2004002745 W 20040825; AU 2004268446 A 20040825; CA 2536906 A 20040825; EP 04769171 A 20040825; IL 17394406 A 20060226; JP 2006524456 A 20040825; KR 20067003852 A 20060224; RU 2006109357 A 20040825